CompanyCBIONasdaqWaltham, MA

Crescent Biopharma, Inc.

Crescent Biopharma develops a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates for solid tumors.

SEC EDGAR ClinicalTrials.gov crescentbiopharma.com

8-KSep 11Latest SEC filing, period to Sep 8

Jul 30Latest story

July 2026

Crescent Biopharma reports Q2 2026 results, cites progress across PD-1 x VEGF and ADC pipeline

Jul 30Quarterly updateCrescent Biopharma, Inc.

Crescent Biopharma prices $117.5 million public offering of shares and warrants

Jul 15FinancingCrescent Biopharma, Inc.

Crescent Biopharma reports about $171.6 million in cash as of June 30, 2026

Jul 14Quarterly updateCrescent Biopharma, Inc.